Herborium Group, Inc. CEO Dr. Agnes P. Olszewski Ph.D., to Be Interviewed on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" on January 17th, 2015

Friday, 16 January 2015 - Editor

Herborium Group, Inc. CEO Dr. Agnes P. Olszewski Ph.D., to Be Interviewed on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" on January 17th, 2015

Live Interview Airs on The Trader's Network Radio Show, Hosted by Michael Yorba, 1:00pm ET/10:00am PT/12:00pm CT

About Herborium Group, Inc.
Herborium Group, Inc. is a novel Botanical Therapeutics® company focused on developing, licensing, and marketing of proprietary, botanical based medicinal products, targeting unmet medical needs. The Company responds to both consumers and healthcare professionals demand for safe, efficacious, all natural medicinal options for treatment and prevention of selected diseases and health concerns.

The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The potential for this market assesses for over $125 billion in the USA, Canada and UK alone.

This new market is presently positioned for exponential growth since it represents a compelling response to changing needs of a healthcare sector. For the industry, botanical therapeutics® provide a value added approach based on product differentiation, higher profit margins, and intellectual property protection with a lower risk and regulatory burden and lower cost. Nutraceuticals (supplements) face increasing FDA and market scrutiny, with massive competitive pressures. To meet the needs of this new growing market opportunity for a diverse spectrum of botanically based drugs, along with complementary and non-traditional therapies; Herborium introduces its own Botanical Therapeutics® defined as "bridge products," an emerging category of natural medicines with clinically and scientifically validated efficacy and safety.

Botanical Therapeutics® represents benefits and attributes of both aforementioned traditional sectors. Botanical Therapeutics® bring the intellectual property value, posology, clinical validation and rapid market entry while maintaining a safety profile of botanical ingredients and offering the benefits of preventive medicine and cost containment. For its own Botanical Therapeutics® the Company adopts clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its proprietary therapeutic candidates from so called "ethnic" medicinal sources such as Traditional Chinese Medicine (TCM) with initial confirmatory data and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western and progressive global markets. This strategy serves to mitigate risk in the product development and marketing strategies. The Company secured a pipeline of botanical ingredient based products in the areas of Dermatologic, Women's Health and Men's Health including selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Short term product portfolio also includes all herbal Energy and Stress Management formula free of caffeine, sugar, Vit. B complex and amino acids. The longer-term pipeline includes Prostate Health (BPH) and Liver Diseases, as well as product extensions in existing product categories and the anti-infectious product candidate focused on antibiotic resistant infections. Herborium Managements represents a unique blend of expertise with over 50 years of successful business dealings in marketing healthcare and consumer products, an exceptional track record in pharmacology and drug development, clinical testing and regulatory affairs in the US and Europe, supported by high standards, know how in herbal science and formulation and global outreach. Herborium presently sells its products in the United States, the United Kingdom, Canada and continental Europe through a network of distributors, specialty retailers, and e-commerce. With initial seed investment brought to the Company by Friends and Family and a small professional round, the Company has developed and deployed a solid and innovative business model that already brings rapidly growing revenues and is ideally positioned for exponential growth in the near future. Down economic times are actually realizing an additional pressure on the sector, and both consumers and insurance companies look for safer and more affordable healthcare options.

HBRM0.0009+12.50%

With both a PhD and an MBA, Dr. Olszewski developed her passion for providing all-natural alternatives and complementary botanical ingredients-based therapies that blend science and nature during an over 20-year strategic management and consulting career that included extensive work in the development and marketing of consumer products, including botanical medicines, beauty and health supplements and nutrition products in the U.S., Europe and China. Her experience includes work on a high-profile biotechnology joint venture in China, where she cultivated relationships with key Chinese business and government officials. Dr. Olszewski also served as Director of the Institute for International Business at Seton Hall University and as Professor of Marketing and International Business prior to founding Herborium.

Since launching Herborium Group, Dr. Olszewski and her team have focused on developing products that combine the best Western and traditional medicine have to offer, meeting unmet wellness needs in the U.S. and Europe. Leveraging the treasure trove of traditional medicines that have been proven effective over the centuries and applying modern scientific standards in development and testing, Herborium currently offers a range of Botanical Therapeutics® that address a variety of conditions, including acne and the controlling symptoms of rosacea, men's and women's sexual health, energy and stress management and in an foreseeable future, Prostate Health. 

Presently, the company's flagship product is AcnEase®, all herbal dermatologic that treats the root cause of acne -- an overproduction of sebum (skin oil) by sebaceous glands, which leads to localized inflammation and scarring -- instead of just acne the symptoms. AcnEase® tablets, a proprietary herbal compound that restores balance and skin health, is up to 96% effective in treating acne and the controlling symptoms of rosacea and works for people who suffer from acne of any type at any age, regardless of gender, skin type and color of complexion. Herborium's Women and Men Sexual formulas and Energy & Stress Management formula are in line to market.

In addition to developing botanical-based medicinal products, Dr. Olszewski is also passionate about educating the public about the benefits -- and potential drawbacks -- of natural medicines. She is a member of the GLG Council and a frequent speaker and writer on the topics of integrated and personalized medicine, natural remedies, wellness and prevention, nutraceutical products and global marketing strategies in a sector. Find out more about Dr. Olszewski and the Herborium Group at www.herborium.com

Union Dental, UDHI, Returns to Profitability

Tuesday, 11 November 2014 - Editor

UNION DENTAL returns to profitability for 3^rd quarter

Coral Springs, Florida, / November 11, 2014 / Union Dental Holdings, Inc. (OTC PK: UDHI) - http://www.uniondental.com/ir-

a Company that operates and manages a network of dentists throughout the United States for union members announced the financial results for the quarter ending September 30, 2014. In the Consolidated Statement of earnings the Company reported a profit of $174,138 as income from operations on revenues of $918,508 as compared to a loss of $38,118 from operations on revenues of $1,026,161 during the same period in 2013.

Dr. George Green, President and CEO stated: “Our revenues were lower for the quarter as compared to last year but we were profitable as opposed to a loss for the same period last year on higher revenues showing our staff can adjust to the volatile economic conditions our nation faces.”

About Union Dental Holdings, Inc., Direct Dental Services, Inc. and

Union Dental Corp.

Direct Dental Services and Union Dental Corp. are wholly owned subsidiaries. Direct Dental Services provides dentists with “areas of exclusivity” to participate with various unions including the Communications Workers of America (CWA) and the International Brotherhood of Electrical Workers (IBEW), United Association of Plumbers and Pipe Fitters (UA) and The Association of Flight Attendants – Communications Workers of America (AFA-CWA). Direct Dental Services receives annual management fees from the dentists in exchange for practicing in these “areas of exclusivity” where CWA and IBEW members use the dentists’ services. Union Dental manages a dental practice in Coral Springs, Florida.

WEBSITE: www.uniondental.com/ir

"Safe-Harbor" Statement: Under the Private Securities Litigation Reform Act of 1995. This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

CONTACT INFORMATION:

Dr. George D. Green, President - This e-mail address is being protected from spambots. You need JavaScript enabled to view it